Displaying items by tag: Highdensity microarray technology

Biotechnology firm Vaxxas has announced a Phase I clinical trial for the first needle-free COVID-19 vaccine candidate which is administered using Vaxxas' proprietary high-density microarray (HD-MAP) technology.

Published in Health

Subscribe to Newsletter

*  Enter the security code shown: img0

WEBINARS & EVENTS

CYBERSECURITY

PEOPLE MOVES

GUEST ARTICLES

Guest Opinion

ITWIRETV & INTERVIEWS

RESEARCH & CASE STUDIES

Channel News

Comments